Gene editing is moving from “interesting biology” to “one-and-done” ambition

Gene editing is moving from “interesting biology” to “one-and-done” ambition

A few people were born with a “broken” form of the PCSK9 gene, and they ended up with low LDL and striking protection from heart disease. That natural oddity helped set off monoclonal antibodies, then small interfering RNA drugs, and now VERVE-102, described here as a first real attempt at permanent gene editing in the liver to put the lid on PCSK9 and lower LDL for good. The piece is careful to note both the excitement and the question marks, which is exactly the right vibe for longevity tech that might someday matter for heart disease and maybe even dementia.

Gobble's Take: Nature found the workaround first; biotech is just trying not to fumble the follow-up.
Source: Perplexity Search (community news)

Women’s hormonal health is getting a personalized-care reset

Sia Health is positioning itself around continuous, personalized care instead of one-time consultations, with medical insight, nutrition, fitness, and lifestyle support in one place. Founder Aditi describes a very specific origin story: diagnosed with PCOS before 15, stuck on hormonal pills for close to five to six years, then eventually using consistent changes in nutrition, fitness, and lifestyle to lose over 20 kilos and bring cycles back toward regularity. The broader message is blunt: the goal is to make women actually feel better, not just get diagnosed.

Gobble's Take: If longevity is supposed to be practical, this is the non-glamorous version that actually sounds usable.
Source: Perplexity Search (community news)

Aging research is now wearing a biotech badge, not a fringe label

The red-light-therapy roundup also points to a bigger shift: research into aging has gone mainstream, and anti-aging has become legitimate biotechnology. It cites Nature’s “Gene clock predicts time to death in humans – and assesses ‘biological’ age,” plus Retro Biosciences raising money at a $1.8 billion valuation while pursuing in vivo gene therapies, cell replacement therapies, and other approaches to spur younger, healthier cells into aging tissues. That is a lot of capital chasing a lot of aspiration.

Gobble's Take: Longevity has officially graduated from “weird hobby” to “serious money with a lab coat.”
Source: Perplexity Search (community news)

In Case You Missed It

Yesterday's top stories:

• Bryan Johnson Just Ditched Your Favorite Longevity Drugs
• The "Love Hormone" Just Got a Longevity Upgrade
• Monkeys Just Got a Biological Age Reset With Stem Cells
• The Common Blood Pressure Drug That Might Also Extend Your Life